For this, we first examined the combinatorial effects of apalutamide and the pan-AKT inhibitor, GSK690693, in vitro using mouse prostate cancer cell lines derived from Pten-deficient CNPC (7109-G4) and CRPC (2945-F12), and Pten/Trp53-deficient CNPC (3902-A1) and CRPC (4522-B8). Here, TP53 is linked to prostate cancer.